Logo image of NERV

MINERVA NEUROSCIENCES INC (NERV) Stock Fundamental Analysis

NASDAQ:NERV - Nasdaq - US6033802058 - Common Stock - Currency: USD

1.82  -0.02 (-1.09%)

Fundamental Rating

1

We assign a fundamental rating of 1 out of 10 to NERV. NERV was compared to 571 industry peers in the Biotechnology industry. NERV has a bad profitability rating. Also its financial health evaluation is rather negative. NERV has a expensive valuation and it also scores bad on growth.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

NERV had negative earnings in the past year.
In the past year NERV has reported a negative cash flow from operations.
In the past 5 years NERV reported 4 times negative net income.
NERV had a negative operating cash flow in each of the past 5 years.
NERV Yearly Net Income VS EBIT VS OCF VS FCFNERV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -20M -40M -60M

1.2 Ratios

With an excellent Return On Assets value of -7.74%, NERV belongs to the best of the industry, outperforming 88.28% of the companies in the same industry.
Industry RankSector Rank
ROA -7.74%
ROE N/A
ROIC N/A
ROA(3y)-58.58%
ROA(5y)-53.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
NERV Yearly ROA, ROE, ROICNERV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 -200 -400 -600

1.3 Margins

NERV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
NERV Yearly Profit, Operating, Gross MarginsNERV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 1 2 3 4

More info and screens

3

2. Health

2.1 Basic Checks

The number of shares outstanding for NERV has been increased compared to 1 year ago.
NERV has more shares outstanding than it did 5 years ago.
NERV has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
NERV Yearly Shares OutstandingNERV Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 2M 4M 6M
NERV Yearly Total Debt VS Total AssetsNERV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 50M 100M 150M

2.2 Solvency

Based on the Altman-Z score of -13.90, we must say that NERV is in the distress zone and has some risk of bankruptcy.
The Altman-Z score of NERV (-13.90) is worse than 80.82% of its industry peers.
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Altman-Z -13.9
ROIC/WACCN/A
WACCN/A
NERV Yearly LT Debt VS Equity VS FCFNERV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 50M 100M

2.3 Liquidity

NERV has a Current Ratio of 6.23. This indicates that NERV is financially healthy and has no problem in meeting its short term obligations.
NERV's Current ratio of 6.23 is fine compared to the rest of the industry. NERV outperforms 62.70% of its industry peers.
NERV has a Quick Ratio of 6.23. This indicates that NERV is financially healthy and has no problem in meeting its short term obligations.
NERV has a Quick ratio of 6.23. This is in the better half of the industry: NERV outperforms 63.06% of its industry peers.
Industry RankSector Rank
Current Ratio 6.23
Quick Ratio 6.23
NERV Yearly Current Assets VS Current LiabilitesNERV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 20M 40M 60M 80M 100M

More info and screens

1

3. Growth

3.1 Past

NERV shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 12.08%, which is quite good.
EPS 1Y (TTM)12.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.57%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

Based on estimates for the next years, NERV will show a quite strong growth in Earnings Per Share. The EPS will grow by 18.54% on average per year.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y93.69%
EPS Next 2Y19.85%
EPS Next 3Y17.07%
EPS Next 5Y18.54%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
NERV Yearly Revenue VS EstimatesNERV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 200M 400M 600M 800M
NERV Yearly EPS VS EstimatesNERV Yearly EPS VS EstimatesYearly EPS VS Estimates 2014 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 0 10 -10 -20 -30

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

NERV reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for NERV. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
NERV Price Earnings VS Forward Price EarningsNERV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
NERV Per share dataNERV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share -1 -2 -3 -4 -5

4.3 Compensation for Growth

A more expensive valuation may be justified as NERV's earnings are expected to grow with 17.07% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y19.85%
EPS Next 3Y17.07%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for NERV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

MINERVA NEUROSCIENCES INC

NASDAQ:NERV (2/21/2025, 8:00:01 PM)

1.82

-0.02 (-1.09%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-05 2024-11-05/bmo
Earnings (Next)03-18 2025-03-18/amc
Inst Owners30.03%
Inst Owner Change-84.6%
Ins Owners4.02%
Ins Owner Change0%
Market Cap12.72M
Analysts43.33
Price Target5.1 (180.22%)
Short Float %0.38%
Short Ratio0.46
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)1
Avg EPS beat(2)18.71%
Min EPS beat(2)-10.17%
Max EPS beat(2)47.58%
EPS beat(4)2
Avg EPS beat(4)-2.44%
Min EPS beat(4)-54.86%
Max EPS beat(4)47.58%
EPS beat(8)3
Avg EPS beat(8)-25.44%
EPS beat(12)5
Avg EPS beat(12)-31.62%
EPS beat(16)7
Avg EPS beat(16)-35.23%
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)0%
EPS NQ rev (3m)-208.25%
EPS NY rev (1m)0%
EPS NY rev (3m)86.73%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)-100%
Revenue NY rev (1m)N/A
Revenue NY rev (3m)-100%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B N/A
P/tB N/A
EV/EBITDA N/A
EPS(TTM)-4.15
EYN/A
EPS(NY)-2.73
Fwd EYN/A
FCF(TTM)-2.92
FCFYN/A
OCF(TTM)-2.92
OCFYN/A
SpS0
BVpS-3.1
TBVpS-5.23
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -7.74%
ROE N/A
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-58.58%
ROA(5y)-53.1%
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity N/A
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 6.23
Quick Ratio 6.23
Altman-Z -13.9
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)12.08%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%47.57%
EPS Next Y93.69%
EPS Next 2Y19.85%
EPS Next 3Y17.07%
EPS Next 5Y18.54%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-16.55%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y19.67%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y19.67%
OCF growth 3YN/A
OCF growth 5YN/A